America's Biggest Crisis: Is This The Cure? | Doug Drysdale

Watch on YouTube ↗  |  January 29, 2025 at 04:04  |  29:10  |  The David Lin Report
Speakers
Doug Drysdale — CEO, Cybin

Summary

David Lin interviews Doug Drysdale, CEO of Cybin, about the U.S. mental health crisis and psilocybin-based medicine. Drysdale explains how psychedelic-assisted therapy may offer rapid, durable relief for depression and anxiety, and discusses FDA, DEA, and political/regulatory dynamics. He also outlines Cybin’s clinical pipeline and argues the company is well funded, undervalued relative to its stage, and has major near-term catalysts.

  • Mental illness affects about one in five U.S. adults annually and one in two over a lifetime.
  • Psilocybin-assisted psychotherapy is being developed as a controlled clinical treatment with rapid and durable effects.
  • Schedule I status and the FDA/DEA approval path are central regulatory hurdles and potential catalysts.
  • RFK Jr. and bipartisan interest are viewed as supportive but not yet decisive for psychedelic policy.
  • Cybin's CYB003 is in Phase 3 for depression, while CYB004 is in Phase 2 for generalized anxiety.
  • Cybin has raised over $350 million, has a roughly $200 million market cap, and points to 2025-2027 catalysts.
Ideas
Doug Drysdale CEO, Cybin 15:10
Undervalued psychedelic biotech with major catalysts
Cybin is developing psilocybin-based treatments CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder with evidence of rapid, durable remission (75% after two doses and about 70% still depression-free at 12 months), a much larger effect size than SSRIs, and mild, transient side effects. It is well funded after raising over $350 million, has a roughly $200 million market cap versus a typical $600–700 million valuation for its stage, and has catalysts including CYB004 Phase 2 data in Q2 2025, CYB003 Phase 3 results by late 2026/early 2027, an expected NDA filing in 2027, FDA breakthrough therapy designation, and improving regulatory/payer acceptance. Management views it as a rare large leap in drug development and a good value entry point.
CYBN HIGH
Up Next
33:01
'High Probability' Market Is Topping, What's Next? | Adrian Day
The David Lin Report · Jan 28
1:16:22
Ray Dalio: US Debt Spiral, How to Avoid Disaster | The All-In Interview
All-In Podcast · Jan 28
56:07
Why There Won't Be An Alt Season This Cycle
1000x Podcast · Jan 28
28:35
Will Trump Send Silver To $100? Change Is Happening Now | Gary Thompson
The David Lin Report · Jan 28
26:41
Why DeepSeek Triggered $1 Trillion Market Crash Today | Keith McCullough
The David Lin Report · Jan 27

This The David Lin Report video, published January 29, 2025, features Doug Drysdale discussing CYBN. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: Doug Drysdale  · Tickers: CYBN